NCT01585805 - Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 15, 2012

Primary Completion Date

December 31, 2024

Study Completion Date

March 6, 2026

Conditions

Locally Advanced Pancreatic AdenocarcinomaMetastatic Pancreatic AdenocarcinomaStage III Pancreatic Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8

Interventions

PROCEDURE

Biopsy

Undergo biopsy

PROCEDURE

Biospecimen Collection

Undergo tumor tissue and blood sample collection

DRUG

Cisplatin

Given IV

PROCEDURE

Computed Tomography

Undergo CT

DRUG

Gemcitabine

Given IV

DRUG

Gemcitabine Hydrochloride

Given IV

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

DRUG

Veliparib

Given PO

Trial Locations (12)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, Harrison

11553

Memorial Sloan Kettering Nassau, Uniondale

11725

Memorial Sloan Kettering Commack, Commack

48109

University of Michigan Comprehensive Cancer Center, Ann Arbor

52621

Chaim Sheba Medical Center, Tel Litwinsky

60426

Ingalls Memorial Hospital, Harvey

60637

University of Chicago Comprehensive Cancer Center, Chicago

63141

Mercy Hospital Saint Louis, St Louis

91031

Shaare Zedek Medical Center, Jerusalem

07920

Memorial Sloan Kettering Basking Ridge, Basking Ridge

M5G 2M9

University Health Network-Princess Margaret Hospital, Toronto

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH